Dong Jae Baek
Overview
Explore the profile of Dong Jae Baek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
286
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kim K, Bae G, Park E, Baek D, Kim C, Jang S, et al.
Biochem Biophys Res Commun
. 2020 Aug;
532(1):145-150.
PMID: 32828534
Intestinal epithelial cells form a barrier between the intestinal lumen and host connective tissues and play an important role in maintaining intestinal nutrient homeostasis. This study investigated effects of Allomyrina...
12.
Kim S, Lee T, Moon H, Ki S, Oh Y, Lee J, et al.
Molecules
. 2020 May;
25(11).
PMID: 32471162
PF-543, the most potent sphingosine kinase (SK) inhibitor, does not demonstrate effective anticancer activity in some cancer cells, unlike other known SK1 inhibitors. PF-543 has a non-lipid structure with a...
13.
Shrestha J, Hwang G, Lee T, Kim S, Oh Y, Kwon Y, et al.
Molecules
. 2019 Dec;
24(23).
PMID: 31810327
Sphingosine-1-phosphate (S1P) regulates the proliferation of various cells and promotes the growth of cancer cells. Sphingosine kinase (SK), which transforms sphingosine into S1P, has two isotypes: SK1 and SK2. To...
14.
Kim K, Bae G, Lee M, Park E, Baek D, Kim C, et al.
Nutrients
. 2019 Jul;
11(7).
PMID: 31277481
larva is a nutritional-worthy future food resource and it contributes to multiple pharmacological functions. However, its antidiabetic effect and molecular mechanisms are not yet fully understood. Therefore, we investigated the...
15.
Kim S, Lee T, Oh Y, Shin S, Lee J, Kim S, et al.
Chem Pharm Bull (Tokyo)
. 2019 Jun;
67(6):599-603.
PMID: 31155566
The PF-543 is known as a potent and selective inhibitor of sphingosine kinase (SK) 1 amongst all the SK inhibitors known to date. In a recently reported study by Pfizer...
16.
Shrestha J, Ki S, Shin S, Kim S, Lee J, Jun H, et al.
Molecules
. 2018 Oct;
23(11).
PMID: 30355990
FTY720 inhibits various cancers through PP2A activation. The structure of FTY720 is also used as a basic structure for the design of sphingosine kinase (SK) inhibitors. We have synthesized derivatives...
17.
Lee T, Moon H, Kim S, Shrestha J, Shin S, Lee J, et al.
Chem Pharm Bull (Tokyo)
. 2018 Oct;
66(10):1015-1018.
PMID: 30270236
FTY720 is employed for the treatment of multiple sclerosis and exerts apoptotic effects on various cancers through protein phosphatase 2A (PP2A) activation. In compound 4, the dihydroxy head group of...
18.
Park E, Lee T, Oh Y, Lee J, Shrestha J, Hong S, et al.
Chem Phys Lipids
. 2018 Jul;
215:29-33.
PMID: 30044952
PF-543 is a non-sphingosine analogue with inhibitory effect against SK1, based on a Ki of 4.3 nM and 130-fold selectivity for SK1 over SK2. Since the development of PF-543, animal...
19.
Bae G, Park E, Baek D, Jun H, Oh Y
Biomed Pharmacother
. 2018 Mar;
101:348-354.
PMID: 29499409
Liquiritigenin (LQ) is a major active component of licorice root, which is a flavone used for treating many diseases, including diabetes. LQ has been shown to exhibit a glucose-lowering effect...
20.
Yin X, Chen X, Sun W, Geng X, Zhang X, Wang J, et al.
Org Lett
. 2017 Jan;
19(3):456-459.
PMID: 28121454
A fully synthetic self-adjuvanting cancer vaccine candidate was constructed through covalent conjugation of invariant natural killer T (iNKT) cell ligand α-galactosylceramide (αGalCer) with sialyl Tn (STn), a representative tumor-associated carbohydrate...